CALL - SPRINTER OPEN END - ELI LILLY & CO | Market Closed - Deutsche Boerse AG 01:43:37 2024-07-12 pm EDT | ||
| 51.03 EUR | +3.34% |
|
| Current month | +5.02% | ||
| 1 month | +16.11% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-07-12 | 51.03 | +3.34% |
| 24-07-11 | 49.38 | -2.18% |
| 24-07-10 | 50.48 | +1.92% |
| 24-07-09 | 49.53 | +1.81% |
| 24-07-08 | 48.65 | +0.70% |
Delayed Quote Deutsche Boerse AG
Last update July 12, 2024 at 01:43 pm EDT
More quotesStatic data
| Product type | Knock-Out ohne Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Vontobel
|
| WKN | VU6FAG |
| ISIN | DE000VU6FAG1 |
| Date issued | 2023-04-18 |
| Strike | 394 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.54 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 51.03 € |
|---|---|
| Lowest since issue | 1.15 € |
| Spread | 0.03 € |
| Spread % | 0.06% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
948.4
USD
Average target price
894.8
USD
Spread / Average Target
-5.65%
- Stock Market
- Certificates
- Certificat
